This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Gilead (GILD) Files NDA for RA Candidate Filgotinib in Japan
by Zacks Equity Research
Gilead's (GILD) new drug application for its JAK1 inhibitor filgotinib seeks treatment of rheumatoid arthritis in adult patients across Japan.
AbbVie (ABBV) Stock Moves -0.44%: What You Should Know
by Zacks Equity Research
AbbVie (ABBV) closed the most recent trading day at $74.33, moving -0.44% from the previous trading session.
5 Excellent GARP Picks Based on Discounted PEG
by Urmimala Biswas
While P/E gives an idea of stocks trading at a discount, PEG helps to find stocks with solid future potential.
The Zacks Analyst Blog Highlights: Cintas, Air Products, Walmart, Target and AbbVie
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Cintas, Air Products, Walmart, Target and AbbVie
Chaos Politics to Slow Growth, or Vice-Versa? Zacks October Market Strategy
by John Blank
Do you start off with slow growth in a given Country, and then voters get angry about it? Or do angry voters, with nothing to complain about, get angry anyways, and slow down their economy's growth?
Chaos Politics to Slow Growth, or Vice-Versa? Zacks October Market Strategy
by John Blank
Do you start off with slow growth in a given Country, and then voters get angry about it? Or do angry voters, with nothing to complain about, get angry anyways, and slow down their economy's growth?
Novartis Reports Additional Data on Spondylitis Drug Cosentyx
by Zacks Equity Research
Novartis (NVS) announces additional positive data from the phase III PREVENT study on spondylitis drug, Cosentyx.
5 Dividend Aristocrats to Buy as October Sees a Shaky Start
by Tirthankar Chakraborty
With things looking dicey for the stock market this October, it's prudent to invest in dividend aristocrats for their risk-adjusted returns.
Vertex Enters Into Collaboration With Privately-Held Ribometrix
by Zacks Equity Research
Vertex (VRTX) inks collaboration agreement with privately-held biotech, Ribometrix, for developing up to three RNA-targeted treatments for serious diseases.
The Zacks Analyst Blog Highlights: AbbVie, Starbucks, Phillips 66, Anheuser-Busch InBev and Square
by Zacks Equity Research
The Zacks Analyst Blog Highlights: AbbVie, Starbucks, Phillips 66, Anheuser-Busch InBev and Square
Top Ranked Income Stocks to Buy for October 2nd
by Zacks Equity Research
Here are three stocks with buy rank and strong income characteristics for investors to consider today, October 2nd.
Top Stock Reports for AbbVie, Starbucks & Phillips 66
by Mark Vickery
Today's Research Daily features new research reports on 12 major stocks, including AbbVie (ABBV), Starbucks (SBUX) and Phillips 66 (PSX).
AbbVie (ABBV) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
AbbVie (ABBV) closed at $75.73 in the latest trading session, marking a +1.18% move from the prior day.
Is AbbVie (ABBV) a Great Value Stock Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
AbbVie (ABBV) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
AbbVie (ABBV) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Here is Why Growth Investors Should Buy AbbVie (ABBV) Now
by Zacks Equity Research
AbbVie (ABBV) could produce exceptional returns because of its solid growth attributes.
AbbVie (ABBV) Gets FDA Nod for Label Expansion of HCV Drug
by Zacks Equity Research
AbbVie (ABBV) gets FDA approval for the label expansion of Mavyret.
This is Why AbbVie (ABBV) is a Great Dividend Stock
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does AbbVie (ABBV) have what it takes? Let's find out.
AbbVie (ABBV) Gains As Market Dips: What You Should Know
by Zacks Equity Research
AbbVie (ABBV) closed at $72.97 in the latest trading session, marking a +0.8% move from the prior day.
AC Immune to Earn Milestone From Lilly for Alzheimer's Drug
by Zacks Equity Research
AC Immune (ACIU) will gain a milestone payment of CHF30 million from partner Eli Lilly for the initiation of the phase I study of ACI-3024, currently being developed to treat Alzheimer's disease.
The Zacks Analyst Blog Highlights: AbbVie, Union Pacific, CSX, Danaher and ONEOK
by Zacks Equity Research
The Zacks Analyst Blog Highlights: AbbVie, Union Pacific, CSX, Danaher and ONEOK
Top Analyst Reports for AbbVie, Union Pacific & CSX
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including AbbVie (ABBV), Union Pacific (UNP) and CSX (CSX).
Novartis Announces New Data on Spondylitis Drug Cosentyx
by Zacks Equity Research
Novartis (NVS) announces new positive data from a phase III study on Cosentyx in patients with active nr-axSpA.
AbbVie (ABBV) Gains As Market Dips: What You Should Know
by Zacks Equity Research
AbbVie (ABBV) closed the most recent trading day at $70.59, moving +0.11% from the previous trading session.
Dividend Growth ETFs for Long Term Investors
by Neena Mishra
Dividend growth ETFs hold companies with solid balance sheets and rising earnings.